Investigators in Project 3 (M. Brenner and B. Savoldo) have tested the safety and antitumor efficacy of T cells expressing a chimeric antigen receptor (CAR) specific for the neuroblastoma (NB)-associated antigen GD2, demonstrating tumor responses in 5/11 patients with refractory/relapsed NB and complete remissions in 3. This study also indicated the importance of costimulatory signals provided to T cells through engagement of their native receptors by specific antigens (in this case by EBV-derived peptides) on host antigen-presenting cells. To reproduce and enhance these effects while avoiding the concomitant complexity of manufacturing virus-specific CTLs and the difficulty of treating EBV-seronegative patients, the investigators predict that engineering the CAR.GD2 molecule to incorporate two costimulatory endodomains in order to enhance CAR+ T-cell expansion and persistence in vivo will improve antitumor efficacy and clinical outcome. Because of the potential toxicities associated with excessive or accelerated T-cell activities, they also incorporated an inducible (dimerizable) caspase-9 (iC9) protein, which rapidly ablated T-cell activity and associated graft-versus -host disease in an earlier trial.
Aim 1 will test this approach in patients with relapsed/refractory NB, using T cells expressing a CAR.GD2 that incorporates the CD28 and OX40 costimulatory endodomains and the iC9 gene suicide switch. The expansion, long-term persistence, and antitumor effects of these engineered T cells will be assessed in Aim 2. Finally, in Aim 3, a mouse model will be used to ask if simultaneously targeting, through native and chimeric receptors, two antigens independently expressed by NB cells will prevent tumor immune escape arising from single antigen loss and will also promote tumor-associated antigen presentation by upregulation of HLA molecules due to the inflammatory cytokines locally secreted by CAR+ T cells. Specifically, we will explore the potential for synergy between GD2.CAR+ T cells and T cells that are transgenic for a high-affinity native (aP) TCR specific for an HI_A-A2-restricted epitope on the cancer testis antigen PRAME, which is abundantly expressed by most NB cells. In our previous funding period project we made use of the EBV-specific CTLs (expressing CAR-GD2) developed by Project 1. In the current proposal we use the iC9 safety gene developed by Project 1 and provide our (3D2-CAR to project 1 in return. If successful, the concept of directing both native and chimeric T cell receptor to tumor cell targets may be adapted to other tumors.

Public Health Relevance

Progress in the current Project 3 has indicated the clear potential of CAR.Gb2-expressing T cells in treatment of high-risk neuroblastoma, although the benefits of such therapy did not extend to all patients Hence, the proposed project seeks to overcome several of the remaining barriers to more widespread use of T-cell therapy for this devastating tumor through further modifications of the CAR molecule.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Mohammed, Somala; Sukumaran, Sujita; Bajgain, Pradip et al. (2017) Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther 25:249-258
Heczey, Andras; Louis, Chrystal U; Savoldo, Barbara et al. (2017) CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther 25:2214-2224
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2017) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol 176:688-704
Tanaka, Miyuki; Tashiro, Haruko; Omer, Bilal et al. (2017) Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res 23:3499-3509
Schmueck-Henneresse, Michael; Omer, Bilal; Shum, Thomas et al. (2017) Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol 199:348-362
Shum, Thomas; Omer, Bilal; Tashiro, Haruko et al. (2017) Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov 7:1238-1247
Tashiro, Haruko; Sauer, Tim; Shum, Thomas et al. (2017) Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther 25:2202-2213
Gomes-Silva, Diogo; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2017) Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep 21:17-26
Szoor, Arpad; Vaidya, Abishek; Velasquez, Mireya Paulina et al. (2017) T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics 6:69-79
Yagyu, Shigeki; Hoyos, Valentina; Del Bufalo, Francesca et al. (2016) Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther Methods Clin Dev 3:16003

Showing the most recent 10 out of 201 publications